Mpm Bioventures 2018, L.P. - Nov 2, 2021 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
10%+ Owner
Signature
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC, the general partner of MPM BioVentures 2018, L.P.
Stock symbol
TRDA
Transactions as of
Nov 2, 2021
Transactions value $
$2,000,000
Form type
4
Date filed
11/4/2021, 05:38 PM
Previous filing
Oct 28, 2021
Next filing
Nov 24, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRDA Common Stock Conversion of derivative security +3.82M 3.82M Nov 2, 2021 See Footnote F1, F2, F3, F4
transaction TRDA Common Stock Conversion of derivative security +509K +13.34% 4.33M Nov 2, 2021 See Footnote F2, F4, F5, F6
transaction TRDA Common Stock Purchase $2M +100K +2.31% $20.00 4.43M Nov 2, 2021 See Footnote F4, F7, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRDA Series A Preferred Stock Conversion of derivative security $0 -27.6M -100% $0.00* 0 Nov 2, 2021 Common Stock 3.82M See Footnote F1, F2
transaction TRDA Series B Preferred Stock Conversion of derivative security $0 -3.68M -100% $0.00* 0 Nov 2, 2021 Common Stock 509K See Footnote F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were converted as follows: 1,733,129 by MPM BioVentures 2014, L.P. ("BV 2014"), 115,596 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 59,655 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 1,778,737 by MPM BioVentures 2018, L.P. ("BV 2018"), 94,538 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 35,105 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. ..
F2 Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.
F3 The shares are held as follows: 1,733,129 by BV 2014, 115,596 by BV 2014(B), 59,655 by AM BV2014, 1,778,737 by BV 2018, 94,538 by BV 2018(B) and 35,105 by AM BV2018.
F4 Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
F5 The shares were converted as follows: 231,139 by BV 2014, 15,417 by BV 2014(B), 7,956 by AM BV2014, 237,222 by BV 2018, 12,608 by BV 2018(B) and 4,682 by AM BV2018.
F6 The shares are held as follows: 1,964,268 by BV 2014, 131,013 by BV 2014(B), 67,611 by AM BV2014, 2,015,959 by BV 2018, 107,146 by BV 2018(B) and 39,787 by AM BV2018.
F7 The shares were purchased as follows: 45,408 by BV 2014, 3,029 by BV 2014(B), 1,563 by AM BV2014, 46,603 by BV 2018, 2,477 by BV 2018(B) and 920 by AM BV2018.
F8 The shares are held as follows: 2,009,676 by BV 2014, 134,042 by BV 2014(B), 69,174 by AM BV2014, 2,062,562 by BV 2018, 109,623 by BV 2018(B) and 40,707 by AM BV2018.

Remarks:

See Form 4 for MPM BioVentures 2014, L.P for additional members of this joint filing.